Heterogeneous Or Solid Phase Assay System (e.g., Elisa, Etc.) Patents (Class 435/7.92)
  • Patent number: 10988519
    Abstract: Provided herein is a recombinant viral vector having packaged therein an expression cassette comprising an engineered complement regulator factor H (fH), wherein the gene encodes a hfH protein variant comprising short consensus repeats (SCRs) 1-4, 6-8, and 17-20. Pharmaceutical compositions containing this vector and plasmids comprising nucleic acid sequences that encode the fH protein variant are also provided.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 27, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Wenchao Song, Damodar Gullipalli, Takashi Miwa
  • Patent number: 10928288
    Abstract: A method of monitoring an immunoassay comprises determining the shape of the flow edge of fluid across an immunoassay region. This allows, for example, early detection of possible errors in the test. The above methods may also be used to provide methods to improve the run conditions of a test during its development. The method may be applied to a competitive assay.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: February 23, 2021
    Assignee: ABBOTT TOXICOLOGY LIMITED
    Inventors: Timothy John Abbott, David Patrick Edward Brookes
  • Patent number: 10921321
    Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VlsE protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: February 16, 2021
    Assignee: Abaxis, Inc.
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Jeremy Walker, Cristina Cuesico
  • Patent number: 10921324
    Abstract: Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 16, 2021
    Assignee: AELAN CELL TECHNOLOGIES, INC.
    Inventors: Victoria Lunyak, James Robert Tollervey
  • Patent number: 10900959
    Abstract: The disclosure relates to a method for quantitatively measuring concentration in an aqueous solution of a water soluble polymer that is functionalized with at least one tracer, wherein the method involves impregnating a flow assay with a test area, introducing the flow assay into a test reader, and using the test reader to compare test data to a calibration curve so as to determine the concentration of the water-soluble polymer. This method allows the determination of residuals concentration in aqueous solution recovered from different industries, including oil and gas produced water, mining fluids, industrial water systems, and water treatment applications.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: January 26, 2021
    Assignee: S.P.C.M. SA
    Inventors: Kimberley MacEwen, Hisham El-Shaffey, Michael Skriba
  • Patent number: 10883961
    Abstract: A detecting method for blood is provided. The method includes the following steps. A sensing device including a base and at least one response electrode is provided, wherein the response electrode is spaced apart from a gate end of the base. Blood including blood cells and targets is disposed on the response electrode. The blood is separated into a first part and a second part, wherein the first part is in contact with the response electrode, and the blood cell count in the first part is less than that in the second part. A voltage is applied on the response electrode, such that an electric field is generated between the response electrode and the gate end of the base, and a detection current generated from the base is measured to detect a characterize of the targets.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: January 5, 2021
    Assignee: National Tsing Hua University
    Inventors: Yu-Lin Wang, Indu Sarangadharan, Shin-Li Wang
  • Patent number: 10875908
    Abstract: The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 29, 2020
    Assignee: DIADEM S.R.L.
    Inventors: Maurizio Memo, Daniela Uberti
  • Patent number: 10866229
    Abstract: A system for molecular mapping includes a semiconductor substrate defining a reservoir to receive a sample of molecules and a nanofluidic channel in fluid communication with the reservoir. The system also includes a plurality of electrodes, in electrical communication with the nanofluidic channel, to electrophoretically trap the sample of molecules in the nanofluidic channel. At least one avalanche photodiode is fabricated in the semiconductor substrate and disposed within an optical near-field of the nanofluidic channel to detect fluorescence emission from at least one molecule in the sample of molecules.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: December 15, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Huaiyu Meng, Rajeev Ram
  • Patent number: 10828507
    Abstract: A system (30) and method for detecting or predicting toxicity induced by radiation therapy. A device (34) is configured for determining polypeptide biomarkers present in a urine sample. At least one processor (36) is programmed to detect or predict radiation toxicity based on one or more polypeptide biomarkers determined to be in the urine sample.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 10, 2020
    Assignee: Koninklijke Philips N.V.
    Inventors: Carolina Ribbing, Katrin Bitter
  • Patent number: 10830727
    Abstract: The application relates to an electrode for use in the electrochemical detection of a target species, wherein the electrode has a planar surface disposed on which are probe molecules that are capable of binding selectively to the target species, wherein the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 10 megaohms cm?2 to 95 megaohms cm?2.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: November 10, 2020
    Assignees: Universidade Estadual Paulista “Julio de Mequita Filho”, Oxford University Innovation Limited
    Inventors: Jason Davis, Paulo Roberto Bueno
  • Patent number: 10823739
    Abstract: The present invention provides novel peptides, compositions, and methods for creating quantitative novel compositions, as well as methods for creating quantitative standards to calibrate analytes. These peptides, compositions, and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers (e.g., Tau). Also provided are kits comprising the peptides or compositions described herein, for use in assays (e.g., sandwich immunoassays).
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: November 3, 2020
    Assignee: SALADAX BIOMEDICAL
    Inventors: Paul Rhyne, Adam J. Simon, Flora Berisha, Robert John Neely, Christopher J. Spedaliere, Claudio Mapelli
  • Patent number: 10753952
    Abstract: The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject or a live or a post-mortem animal using oral fluid collected from the post-mortem subject or live or post-mortem animal. The method comprises collecting a sample of oral fluid from a post-mortem subject or a live or a post-mortem animal, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal, and identifying the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: August 25, 2020
    Inventor: Amy J. Reisinger
  • Patent number: 10755406
    Abstract: Described herein are methods for co-expression analysis of multiple markers in a tissue sample comprising: computing a heat map of marker expression for each of a plurality of single marker channel images, wherein each of the plurality of single marker channel images comprise a single marker; identifying one or more candidate regions of interest in each heat map of marker expression; computing overlay masks comprising the identified one or more candidate regions of interest from each heat map of marker expression; determining one or more co-localized regions of interest from the overlay masks; mapping the one or more co-localized regions of interest to a same coordinate position in each of the plurality of single marker channel images; and estimating a number of cells in at least one of the determined one or more co-localized regions of interest in each of the plurality of single marker channel images.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 25, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Michael Barnes, Christophe Chefd'hotel, Ting Chen, Shalini Singh, Alisa Tubbs
  • Patent number: 10739347
    Abstract: A bioassay for the detection of multiple target analytes that includes living immunocytes of a plurality of predetermined types; a signal-generating reporter within each immunocyte that is responsive to predetermined changes occurring within the immunocyte and that includes a bioluminescent protein linked to a fluorescent protein; a signal transduction pathway associated with each signal-generating reporter that is operative to induce the predetermined changes within each immunocyte; a detector element associated with the signal transduction pathway that is operative to trigger the signal transduction pathway; an analyte binding element associated with the detector element that is specific to both the detector element and a target analyte; and wherein upon the binding of an analyte binding element to which a target analyte is also bound to the detector element, the detector element triggers the signal transduction pathway causing the predetermined changes to occur within the living biological cell, thereby ca
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: August 11, 2020
    Assignee: Fundamental Solutions Corporation
    Inventors: M. Russell Williams, Joel Lwande, Shengwen Liang, Kyle McQuaid
  • Patent number: 10725052
    Abstract: The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: July 28, 2020
    Assignee: IDEXX LABORATORIES, INC.
    Inventors: Mahalakshmi Yerramilli, Giosi Farace, John J. Quinn, Murthy V. S. N. Yerramilli
  • Patent number: 10711185
    Abstract: A reagent for performing a chemiluminescent reaction includes luminol or luminol derivatives, an oxidant, an electron mediator, and an enhancer. The enhancer is a nitrogen-containing fused heterocyclic compound having at least two nitrogen atoms. The present disclosure further provides a kit for performing a chemiluminescent reaction comprising the aforesaid reagent.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: July 14, 2020
    Assignee: BIO-HELIX CO., LTD.
    Inventors: Cheng-Yen Lee, Chia-Wen Lien
  • Patent number: 10656163
    Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: May 19, 2020
    Assignee: Wallac Oy
    Inventors: Tarja Ahola, Heikki Kouru, Mikko Sairanen
  • Patent number: 10655163
    Abstract: Described herein are methods, compositions, kits and systems for multiplexed detection of target molecules from a sample. In some embodiments, the methods, compositions, kits and systems can be used to perform multiplexed protein analysis of a sample (e.g., a sample comprising a small number of cells or a single-cell sample). In some embodiments, the same sample subjected to a multiplexed protein analysis using the methods, compositions, kits and systems described herein can also be subjected to a nucleic acid (e.g., RNAs, microRNAs, and/or DNA) analysis, thereby creating an integrated expression profiling from a limited amount of sample.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: May 19, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ralph Weissleder, Sarit S. Agasti, Vanessa M. Peterson, Adeeti Ullal
  • Patent number: 10634671
    Abstract: The invention relates to a method for in situ imaging of samples by cycle multiplexing that enables imaging of various molecular targets through multi-molecular read-outs on the same sample in a rapid, highly sensitive and reliable manner. The invention is further related to imaging buffers preventing the degradation of the sample and of the imaging reagents, which are particularly useful in a method of in situ imaging of samples by cycle multiplexing according to the invention.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: April 28, 2020
    Assignee: LUNAPHORE TECHNOLOGIES SA
    Inventors: Ata Tuna Ciftlik, Diego Gabriel Dupouy, Pierre Joris, Martin Gijs
  • Patent number: 10604699
    Abstract: Provided are an organic rare-earth solid micelle, a preparation method therefor, and a method for increasing the photoelectric conversion efficiency of a solar battery. A small organic conjugated ligand is taken as a first ligand, an amphiphilic diblock polymer is taken as a second ligand, and the first ligand and the second ligand are mixed and doped with a rare-earth chloride solution, and self-assembled to form an organic rare-earth solid micelle, whereby the fluorescence emission intensity and the fluorescence efficiency of the rare-earth element are improved. Next, the prepared organic rare-earth solid micelle is spin coated on an ITO layer of a solar battery, to prepare a solar battery with the organic rare-earth solid micelle. Therefore the sunlight absorption of a cell is increased, and the photoelectric conversion efficiency is improved. The preparation process is simple, low in cost, high in photoelectric conversion efficiency, and environmentally friendly.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: March 31, 2020
    Assignee: Qingdao University
    Inventors: Jianguo Tang, Die Wang, Wenfei Shen, Xinzhi Wang, Yao Wang, Linjun Huang, Jixian Liu, Jiqing Jiao, Yanxin Wang, Wei Wang, Xiaolin Zhang, Fanchen Bu, Jing Wang, Yan Song, Huihui Yang, Xingqin Xu, Laurence A. Belfiore
  • Patent number: 10564084
    Abstract: Disclosed is a process and device allowing for fast measurements of the physicochemical properties of amphiphiles (lipids, surfactants, soaps, . . . ). A Marangoni flow is created and characterized using amphiphiles to be characterized. The observed flow is characterized, and using the disclosed process, one can deduce from this measurement many important physicochemical parameters of the amphiphiles such as their critical micellar concentration. Compared to existing techniques, the disclosed process offers the advantage that it requires a single experiment to deduce the parameters, when other techniques (pendant drop method, conductometry, etc . . . ) require the measurement of a quantity (interfacial tension, conductometry) against a systematically varied parameter (amphiphile concentration, . . . ). The disclosed process and devices are ideal to characterize and/or screen rapidly amphiphiles molecules based on their interaction with a solvent.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 18, 2020
    Assignees: THE TRUSTEES OF PRINCETON UNIVERSITY, CNRS-CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE RENNES I, CHANCELLOR, MASTERS & SCHOLARS OF UNIV. OF OXFORD
    Inventors: Matthieu Roche, Howard A. Stone, Isabelle Cantat, Arnaud Saint-Jalmes, Ian Griffiths, Sebastien Le Roux, Zhen Zhen Li
  • Patent number: 10564151
    Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 18, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Schraeml, Markus Roessler, Michael Gerg
  • Patent number: 10514604
    Abstract: Topcoat compositions are provided that are suitably applied above a photoresist composition. Preferred topcoat compositions comprise a first polymer that comprises (i) first units comprising a nitrogen-containing moiety that comprises an acid-labile group; and (ii) second units that (1) comprise one or more hydrophobic groups and (2) are distinct from the first units.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 24, 2019
    Assignee: Rohm and Haas Electronic Materials Korea Ltd.
    Inventors: Chang-Young Hong, Eui-Hyun Ryu, Min-Kyung Jang, Dong-Yong Kim, Jae Yun Ahn
  • Patent number: 10509046
    Abstract: Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: December 17, 2019
    Assignee: Randox Laboratories Limited
    Inventors: Ivan McConnell, Peter Fitzgerald, Philip Lowry, Elouard Benchikh
  • Patent number: 10509031
    Abstract: A method for providing quality control on a lateral flow assay device or for triggering a process-related step, the device including a substrate having at least one sample receiving area, at least one reagent zone downstream and in fluid communication with the at least one sample receiving area, at least one detection zone downstream and in fluid communication with the at least one reagent zone and at least one wicking zone downstream of the at least one detection zone, each fluidly interconnected therewith along at least one fluid flow path. The detection material provided in the at least one reagent zone produces a detectable signal that can be tracked and monitored prior to the completion of at least one test being performed on the lateral flow assay device.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 17, 2019
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Zhong Ding, James E. Robinson, David A. Tomasso, David A. Heavner
  • Patent number: 10494436
    Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 3, 2019
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Carlos Ricardo Rodrigues Dos Reis
  • Patent number: 10466238
    Abstract: The present invention fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of these immunogenic peptides is controlled by immunological assays based on antibodies reactive against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: November 5, 2019
    Assignee: UNIVERSIDAD DE SEVILLA
    Inventors: Carolina Sousa Martin, Isabel Comino Montilla, Ana Real Calderon, Santiago Vivas Alegre, Angel Cebolla Ramirez
  • Patent number: 10451636
    Abstract: The invention provides a method for screening for and detection of solid organ graft rejection in a subject that comprises assaying a patient sample of plasma, serum or blood from the subject for a protein marker identified herein. An elevated or reduced amount of marker present in the patient sample compared to a control sample is indicative of rejection, and identifies subjects in need of biopsy or modified treatment. The method can be used to screen for patients in danger of transplant rejection without having to undergo more costly, risky and invasive biopsy procedures.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: October 22, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Elaine F. Reed, Hans Albin Gritsch, Jeffrey Lorne Veale
  • Patent number: 10444182
    Abstract: According to one embodiment, a semiconductor device includes FET having a threshold changing according to a chemical state in a gate portion, a time-varying signal application section configured to apply a time-varying signal to at least one of a source, a drain and a back gate of the FET, and a signal reading section configured to read a change in the threshold of the FET resulting from the application of the time-varying signal as a signal.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: October 15, 2019
    Assignee: Kabushiki Kaisha Toshiba
    Inventor: Kaita Imai
  • Patent number: 10436800
    Abstract: Provided are methods of determining if a subject has a cardiac disorder or is at risk for developing a cardiac disorder.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: October 8, 2019
    Assignee: SARCOTEIN DIAGNOSTICS, LLC
    Inventors: Darryl Steven Shaw, Neil Gavin Shaw
  • Patent number: 10434137
    Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the the proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, including peptides and/or interfering RNA and/or lipidic compounds, the agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 8, 2019
    Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
  • Patent number: 10422799
    Abstract: A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 24, 2019
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Mayumi Yoshida, Mitsuaki Yamamoto, Shinya Yokokawa, Tomo Shimizu, Keigo Kono
  • Patent number: 10416156
    Abstract: A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: September 17, 2019
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Mayumi Yoshida, Mitsuaki Yamamoto, Shinya Yokokawa, Tomo Shimizu, Keigo Kono
  • Patent number: 10392665
    Abstract: The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: August 27, 2019
    Assignee: Sera Prognostics, Inc.
    Inventors: John Jay Boniface, Andrew Gassman, Jeff Flick, Chad Bradford, Ashoka Polpitiya, Tracey Cristine Fleischer, Durlin Edward Hickok, Paul Kearney, Gregory Charles Critchfield
  • Patent number: 10386276
    Abstract: Techniques for phosphoprotein detection, quantification, and purification using a chip-based pillar array are provided. In one aspect, a method for purifying a protein sample includes: introducing a mixture including the protein sample and an antibody to a nanoDLD array having a plurality of pillars separated by a gap g, wherein the antibody and proteins in the protein sample form antibody-protein complexes having a size that is greater than a size threshold of the nanoDLD array created by the gap g which permits size-based separation of the antibody-protein complexes as the mixture flows through the nanoDLD array; and collecting a purified protein sample containing the antibody-protein complexes from the nanoDLD array. A lab-on-a-chip (LOC) device including the nanoDLD array is also provided.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 20, 2019
    Assignee: International Business Machines Corporation
    Inventors: Stacey M. Gifford, Gustavo A. Stolovitzky, Benjamin H. Wunsch
  • Patent number: 10369564
    Abstract: Disclosed are devices, kits, compositions, and methods for collecting, transporting, and detecting toxicants, pathogens, and biomarkers in a biological sample. The devices, kits, compositions and methods may be utilized to collect and transport dried blood samples from a skin prick and detect toxicants, pathogens, and biomarkers in the dried blood samples.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: August 6, 2019
    Assignee: Northwestern University
    Inventors: William E. Funk, Thomas W. McDade, Andrew Unger
  • Patent number: 10364286
    Abstract: The invention relates to a novel use of monoclonal anti-alpha-synuclein antibodies. The antibodies can be used to prevent tau aggregation and thereby treating tauopathies such as Alzheimer's disease.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 30, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Karina Fog, Jeppe Falsig Pedersen
  • Patent number: 10359406
    Abstract: Disclosed are biomarkers for preeclampsia including elevated levels of free hemoglobin, including free fetal haemoglobin and the ratio of free fetal hemoglobin to total free hemoglobin. Also disclosed are methods of treating preeclampsia using a therapeutic agent that reduces free circulating hemoglobin levels.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: July 23, 2019
    Assignee: A1M PHARMA AB
    Inventors: Stefan Hansson, Bo Åkerström
  • Patent number: 10342471
    Abstract: A biological fluid sampling transfer device adapted to receive a multi-component blood sample is disclosed. After collecting the blood sample, the biological fluid sampling transfer device is able to separate a plasma portion from a cellular portion. After separation, the biological fluid sampling transfer device is able to transfer the plasma portion of the blood sample to a point-of-care testing device. The biological fluid sampling transfer device also provides a closed sampling and transfer system that reduces the exposure of a blood sample and provides fast mixing of a blood sample with a sample stabilizer. The biological fluid sampling transfer device is engageable with a blood testing device for closed transfer of a portion of the plasma portion from the biological fluid sampling transfer device to the blood testing device. The blood testing device is adapted to receive the plasma portion to analyze the blood sample and obtain test results.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: July 9, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: Bradley M. Wilkinson, Daniel J. Marchiarullo, Gary D. Fletcher
  • Patent number: 10302657
    Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 28, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Barbara Denk, Martin Hund
  • Patent number: 10300108
    Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: May 28, 2019
    Assignees: Astute Medical, Inc., University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Paul McPherson, John A. Kellum
  • Patent number: 10267802
    Abstract: Cellular markers indicating a poor prognosis for ovarian cancer patients are disclosed. In particular, the invention relates to methods utilizing the frequency of a subset of cells in ovarian tumor tissue expressing vimentin, cMyc, or HE4, or any combination thereof, to predict an ovarian cancer patient will relapse.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 23, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jonathan Berek, Wendy Fantl, Veronica Gonzalez, Garry P. Nolan, Nikolay Samusik
  • Patent number: 10254279
    Abstract: A system and method includes a test container for detecting a target substance in a consumable sample, where the test container includes a test container body defining a test container top, a test container bottom opposing the test container top, a first chamber proximal the test container top, and a second chamber proximal the test container bottom, a magnetic diaphragm situated between the first chamber and the second chamber, the magnetic diaphragm obstructing flow of the consumable sample, and the magnetic diaphragm including a magnetic element embedded in the magnetic diaphragm, and a driving element geometrically complementary to the first chamber, the driving element including a consumable sample grinding feature protruding from a surface of the driving element.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: April 9, 2019
    Assignee: Nima Labs, Inc.
    Inventors: Scott Sundvor, Steven Portela, Jonathan Ward, John Walton, Jonathan William Kiel, Jeffrey Mekler, Shireen Yates, Jacob Mooney, Dane Weitmann, Joseph Horrell
  • Patent number: 10234462
    Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Sara Arab, Georg Hess, Hendrik Huedig, Peter Liu, Ursula-Henrike Wienhues-Thelen
  • Patent number: 10222375
    Abstract: The machine is configured to perform an automated rapid plasma reagent (RPR) agglutination test or other agglutination test. The machine includes a sample rack with multiple sample locations thereon and a reagent rack for storing of reagent. A shaker assembly supports at least one microtiter plate or other well supporting structure thereon with a plurality of wells in the plate. An automated pipette accesses samples and reagent and deposits them within wells of the microtiter plate. The shaker assembly shakes multiple samples within the wells of the microtiter plate. Finally, a camera photographs the wells of the plate, preferably from above with a light source below and the plate at least partially transparent. The image is then analyzed in an automated fashion to determine whether a ring of contrast material has remained smooth indicative of a non-reactive sample or has agglutinated/clumped together indicative of a reactive sample.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: March 5, 2019
    Assignee: Gold Standard Diagnostics
    Inventors: Peter Van Praet, Jennifer Roth, John Griffiths
  • Patent number: 10213459
    Abstract: Mitochondrial compositions and therapeutic methods of using same. Compositions of partially purified functional mitochondria and methods of using the compositions to treat conditions which benefit from increased mitochondrial function by administering the compositions to a subject in need thereof.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: February 26, 2019
    Assignee: MINOVIA THERAPEUTICS LTD.
    Inventors: Natalie Yivgi-Ohana, Uriel Halavee
  • Patent number: 10202635
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 12, 2019
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 10195580
    Abstract: A method of creating a mask on a surface of a substrate is disclosed. The substrate comprises a plurality of spaced heating elements on or proximal to the surface. The method comprises applying a layer of masking material to the surface and employing the heating elements to apply energy to a phase change in the masking material at the selected sites such that it adheres to the surface or can be displaced from the surface to mask or unmask the selected sites respectively. A method of synthesising an array of molecules, an apparatus for selectively masking one or more sites on a surface and a semi-conductor chip that uses micro-heaters to modulate a masking layer on areas of the chip surface.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: February 5, 2019
    Assignee: EVONETIX LTD.
    Inventors: Daniel Arthur Hall, Christopher John Favero Jordan
  • Patent number: 10175258
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: January 8, 2019
    Assignee: RANDOX LABORATORIES LIMITED
    Inventors: Stephen Peter Fitzgerald, Paul John Innocenzi, Ivan Robert McConnell, Philip Andrew Lowry, Elouard Benchikh
  • Patent number: 10174370
    Abstract: The present invention relates to a non-destructive method for analyzing maternal DNA of a seed. In this method the DNA may be dislodged from the seed coat surface and may be used to collect information on the genome of the maternal parent of the seed. Also, the present invention provides a high throughput DNA analysis system for large plant populations.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 8, 2019
    Assignee: RIJK ZWAAN ZAADTEELT EN ZAADHANDEL B.V.
    Inventor: Cornelis Maria Petrus Van Dun